|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, cellular context determines the p53 transcriptional target selection. p53-dependent apoptosis was induced in Lgr5-expressing stem cells of the small intestine and high p53 transcriptional activity and apoptosis was induced in intestinal adenomas and in xenograft tumors.
|
31138526 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the spheroid-derived xenograft tumors, NOX1 is preferentially expressed in LGR5-positive cells.
|
31365870 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR-5) is a novel biomarker, particularly in stem cells, and is involved in embryogenesis, tumor development, and tumor cell signal transduction.
|
31126119 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LGR5(<sup>+</sup>) CSCs cells were shown to interconvert with more drug-resistant LGR5(<sup>-</sup>) cancer cells, and treatment with LGR5-targeted antibody-drug conjugates (ADC) eliminated LGR5(<sup>+</sup>) tumors, yet a fraction of LGR5(<sup>-</sup>) tumors eventually recurred.
|
31444231 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lgr5 showed a protection against the inhibition of Dox on the growth of tumor subcutaneously injected.
|
31244936 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Levels of UBE2C, LGR5, VM, and MVD were all positively associated with tumor stages, lymph node metastasis (LNM) stages, tumor grades, and tumor-node-metastasis (TNM) stages, and unfavorably with patients' overall survival (OS) and disease-free survival (DFS).
|
31008954 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In colorectal tumour xenografts and APC<sup>min/+</sup> transgenic mice, administration of salinomycin significantly reduced tumour growth and the expression of CSC-related Wnt target genes including LGR5.
|
31236922 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Reduced LGR5 expression in tumor cells was associated with worse prognosis in PDAC.
|
31543221 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The interaction between Lgr5 and the immune-related tumor microenvironment is not completely understood.
|
31417548 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High levels of LGR5 expression were significantly associated with tumor size (p = 0.002), LN metastasis status (p = 0.044), and triple-negative breast cancer (p = 0.029), consistent with our findings from the ONCOMINE database.
|
29471794 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Prior to drug conjugation, we evaluated two different anti-LGR5 monoclonal antibodies (mAbs), 8F2 and 9G5, using <sup>89</sup>Zr-immunoPET to select the optimal mAb for ADC development and tumor imaging.
|
29718672 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that LGR5 expression in the epithelium and stroma was associated with tumor stage, and by integrating functional experiments with LGR5-sorted cell RNA sequencing data from adenoma and normal organoids, we found correlations between LGR5 and CRC-specific genes, including dickkopf WNT signaling pathway inhibitor 4 (<i>DKK4</i>) and SPARC-related modular calcium binding 2 (<i>SMOC2</i>).
|
29467240 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In both mouse and human BCC, this persisting, slow-cycling tumour population expresses LGR5 and is characterized by active Wnt signalling.
|
30297799 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Lgr5 expression was found in 82.4% (168/204) cases, significantly more common in neoplastic cells at the infiltrative front (<i>n =</i> 59.5%, 110/185) or at the expanding front (<i>n =</i> 36.4%, 59/162) than at the tumor center (<i>n =</i> 16.7%, 34/204; <i>P</i> < 0.01).
|
30046385 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
LGR5 expression in tumor specimens and adjacent tissue resected from 66 patients were detected by immunohistochemistry.
|
30108439 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A cluster (termed cluster SIE) based on cancer stemness markers (Nanog, Lgr5, CD44v6, ALDH1A1 in TC), EMT markers (E-cadherin, Snail in TC), and immune-cell markers (CD4<sup>+</sup> and CD8<sup>+</sup> T-lymphocyte counts in TC, and CD68<sup>+</sup> macrophages in tumor invasive front) could significantly predict 5-year survival (P = .040).
|
29921496 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Previously, we reported that doublecortin like kinase 1 (Dclk1) marks tumor stem cells but not normal stem cells in the intestine of Apc<sup>Min/+</sup> mice, and that Dclk1- and Lgr5-double positive tumor cells are the tumor stem cells of intestinal tumors.
|
30001952 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Aberrant expression of LGR5 was significantly associated with patient age (P = 0.006), tumor histologic type (P < 0.001), and distant metastasis (P = 0.025).
|
29777575 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We compared stemness traits of colon CSCs by cell surface marker (CD133 and Lgr5) and functional assays, such as chemoresistance, colony formation, cell adhesion, invasion and tumour-formation assay.
|
30220706 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
LGR5 overexpression attenuated tumor growth by decreasing ERK phosphorylation along with decreased colony formation and migration abilities in DLD1 cells.
|
30036518 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This review will recap the various oncogenic and tumour suppressive roles that have been described for the LGR5 molecule in CRC.
|
29844449 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All cases contained tumor cells with some LGR5-positive dots.
|
30043418 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Clonal analysis using ubiquitous multicolor lineage tracing revealed that colon tumors derived from Lgr5-positive cells were monoclonal in origin but eventually merged with neighboring tumors, producing polyclonal tumors at the later stage.
|
28176811 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Lgr5 expression was significantly correlated with lymph node metastasis, increased depth of invasion, increased tumor size, advanced differentiation, higher AJCC stage and poorer survival.
|
28404917 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Selective ablation of LGR5<sup>+</sup> CSCs in LGR5-iCaspase9 knock-in organoids leads to tumour regression, followed by tumour regrowth driven by re-emerging LGR5<sup>+</sup> CSCs.
|
28355176 |
2017 |